Cypros Pharmaceutical receives notice of allowance from U.S. Patent and Trademark Office for its cardio/neuroprotective agent.CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 4, 1995--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPR) Friday announced it has received a notice of allowance for the issuance of a composition of matter patent from the U.S. Patent and Trademark Office (the PTO PTO abbr. 1. Parent Teacher Organization 2. or p.t.o. please turn over 3. power takeoff PTO or pto please turn over Noun 1. ). The patent, expected to be issued shortly, covers a broad class of novel adenosine adenosine /aden·o·sine/ (ah-den´o-sen) a purine nucleoside consisting of adenine and ribose; a component of RNA. It is also a cardiac depressant and vasodilator used as an antiarrhythmic and as an adjunct in myocardial perfusion imaging metabolism inhibitors being developed as cardioprotective and neuroprotective agents. The company is also currently in the process of filing patents for this class of novel adenosine metabolism inhibitors in Europe and Japan. Adenosine is a natural byproduct by·prod·uct or by-prod·uct n. 1. Something produced in the making of something else. 2. A secondary result; a side effect. Noun 1. of cellular energy utilization whose levels are increased during and after ischemia (low blood flow) as it occurs in heart attack and stroke victims. During these episodes, adenosine functions as a natural cellular protective agent. However, adenosine stores are quickly depleted de·plete tr.v. de·plet·ed, de·plet·ing, de·pletes To decrease the fullness of; use up or empty out. [Latin d by an active metabolic process, and this limits the natural protective roles of adenosine. The Cypros compounds moderate this metabolic process, thereby extending the cytoprotective benefits of adenosine. Dr. Paul J. Marangos, president and chief executive officer, stated, "This most recent notice of allowance represents more comprehensive patent coverage than was previously allowed by the PTO and adds to our growing patent estate in cytoprotective drugs. "Our unique adenosine regulating compounds hold significant promise as cytoprotective drugs since they are derived from agents with known cytoprotective properties. We are currently studying several of the most promising compounds in preclinical models with the goal of selecting a clinical candidate." Cypros Pharmaceutical is developing small-molecule drugs that protect cells from ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic injury. The company is pursuing multiple cytoprotective drug development strategies, including clinical programs which augment anaerobic anaerobic /an·aer·o·bic/ (an?ah-ro´bik) 1. lacking molecular oxygen. 2. growing, living, or occurring in the absence of molecular oxygen; pertaining to an anaerobe. metabolism (CPC-111 and CPC-211), and early-stage research programs in neuronal calcium channel antagonists, glial glial /gli·al/ (gli´'l) of or pertaining to the neuroglia. glial of or pertaining to glia or neuroglia. glial limitans a dense network of glial processes at the pia mater. chloride channel blockers, and adenosine metabolism inhibitors for which it is currently seeking research and development partners. The company has two lead product candidates, CPC-111 (currently in Phase II trials for patients with decompensating heart failure, and cardiac bypass) and CPC-211 (currently in a Phase II trial in ischemic stroke). CONTACT: Cypros Pharmaceutical Corp., Carlsbad David W. Nassif, 619/929-9500 or Financial Sciences of America Francesca Daniels, 310/278-4413 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion